Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
OPRX - OptimizeRx Corp.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$10.25
DETAILS
HIGH:
$12.00
LOW:
$7.00
MEDIAN:
$11.00
CONSENSUS:
$10.25
UPSIDE:
23.79%
Stock News
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook
OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON)
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership. Risk and Volatility OptimizeRx has a beta of 1.09,
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence
New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced that management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 10, 2026, in New York, NY.
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Troy Sarich as a Company advisor.
AWM Investment Company Inc. Invests $1.38 Million in OptimizeRx Corp. $OPRX
AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ: OPRX) in the undefined quarter, according to the company in its most recent filing with the SEC. The firm acquired 240,421 shares of the company's stock, valued at approximately $1,375,000. AWM Investment Company Inc. owned about 1.28% of OptimizeRx as of
Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX
Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 563,570 shares of the company's stock after buying an additional 102,661 shares during the
OptimizeRx Q2 Earnings Call Highlights
OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its earnings call. The company reaffirmed its full-year revenue outlook of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million.
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million– Completed debt refinancing with $35 million traditional banking facility, including $25 million term loan and $10 million undrawn revolver; repaid $8.3 million of principal since inception
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a conference call on Wednesday, August 12, 2026, at 4:30 p.m.
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer.
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
Price Targets
OptimizeRX (OPRX) PT Raised to $11 at Citizens: Positioned for Return to Growth in 2027
$11.00
(was $8.78)
UBS
OptimizeRx price target lowered to $12 from $14 at Stifel
$12.00
(was $7.04)
Stifel Nicolaus
OptimizeRx price target lowered to $10 from $11 at B. Riley
$10.00
(was $4.79)
UBS
OptimizeRx price target lowered to $11 from $20 at Lake Street
$11.00
(was $4.86)
Lake Street
OptimizeRx price target lowered to $7 from $10 at Stephens
$7.00
(was $6.34)
Stephens
OptimizeRx price target lowered to $14 from $17 at Stifel
$14.00
(was $6.34)
Stifel Nicolaus
OptimizeRX (OPRX) PT Lowered to $17 at Stifel After Flattish Q4 Revenue
$17.00
(was $6.80)
David Grossman
·
Stifel Nicolaus
OptimizeRx price target raised to $23 from $20 at Citizens JMP
$23.00
(was $18.29)
UBS
JMP Securities Starts OptimizeRX (OPRX) at Market Outperform, 'Comprehensive Biopharma Digital Marketing Platform'
$15.00
(was $11.17)
Constantine Davides
·
JMP Securities